AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$AVTX

Doyle Mittie sold $20K of AVTX

Doyle Mittie (Chief Medical Officer) sold 1,000 shares of Avalo Therapeutics, Inc. (AVTX) at $20.00 on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Doyle Mittie
Published Aug 19, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AVTX
Neutral
high confidence
Mentioned
$AVTX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVTXNeutralLow
01

Why it matters

The transaction is modest and does not suggest a change in company fundamentals.

02

Market read

Limited relevance; primarily a compliance disclosure.

03

What to watch

Potential upcoming clinical data could influence insider behavior.

Relevance 2/10Novelty 3/10Timing: filed today

Background

Form 4 filing by Avalo Therapeutics' CMO shows a routine 10b5-1 sale.

Company-level read

Ticker impact

$AVTXNeutralHigh confidence
Context

Chief Medical Officer sold 1,000 shares for $20,000 via a 10b5-1 plan.

Expected impact

No material impact on stock price.

Evidence & confidence

The sale is small relative to total holdings and disclosed via a routine filing.

Market effects

Sector

None; insider sale does not affect biotech sector.

Regional

None; limited to company level.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal confidence issues.

Key entities

  • Company
    Avalo Therapeutics, Inc.

    Biotech firm listed on Nasdaq under AVTX.

  • Insider
    Doyle Mittie

    Chief Medical Officer of Avalo Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AVTX insider trading history →

Related articles

SEP 10
$AVTXMedAI 8/10

AVTX: Advancing anti-IL-1 beta therapy to phase III for HS, expanding indications, and securing strong financial support

Avalo Therapeutics (AVTX) is advancing its anti-IL-1 beta antibody, abdakibart, to phase III trials for hidradenitis suppurativa (HS) after positive phase II results. The company plans to expand indications in dermatology and rheumatology, develop a long-acting version, and secure financial support. The strategy includes differentiated dosing and device approaches.

tradingview.com1 min
AUG 6
$AVTXMedAI 8/10

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics (Nasdaq: AVTX) reported Q2 2026 results and business updates. The company plans to start a registrational Phase 3 for abdakibart in hidradenitis suppurativa in H1 2027 and expects to submit an IND for AVTX-010 in H1 2027. Cash, cash equivalents and investments were $472.2M at June 30, 2026, funding operations into 2029. Q2 net loss was $36.4M.

finanznachrichten.de6 min
AUG 6
$AVTXMed

Avalo Therapeutics, Inc. (AVTX): Results of Operations and Financial Condition

Avalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates • Plans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027 • Expanded pipeline with AVTX-010, a lon

SEC EDGAR 8-K6 min